CN103932914A - Chitosan mouthwash and preparation method thereof - Google Patents
Chitosan mouthwash and preparation method thereof Download PDFInfo
- Publication number
- CN103932914A CN103932914A CN201310392974.4A CN201310392974A CN103932914A CN 103932914 A CN103932914 A CN 103932914A CN 201310392974 A CN201310392974 A CN 201310392974A CN 103932914 A CN103932914 A CN 103932914A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- polylysine
- mouthwash
- purified water
- natamycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
A chitosan mouthwash and a preparation method thereof are provided. Effective ingredients of the chitosan mouthwash comprise chitosan, natamycin, polylysine and aspartame, and the chitosan mouthwash also comprises mint oil, a lemon essence and purified water. The preparation method comprises the steps: taking purified water, adding chitosan, natamycin, polylysine and aspartame according to the amount, and heating to dissolve; after being cooled, adding the essence and the mint oil, additionally adding purified water to full amount of the mouthwash, determining the pH value, and thus obtaining the product. Compared with the prior art, because two broad-spectrum antibacterial agents of polylysine and natamycin are added into chitosan, the prepared mouthwash fully plays the advantages of the three kinds of drugs respectively in a bacteriostatic aspect.
Description
[technical field]
The invention belongs to a kind of chitosan collutory and preparation method thereof.
[background technology]
Oral disease is a kind of common disease, and main manifestations is the symptoms such as gingivitis, dental plaque, oral ulcer, periodontitis, aphtha of the mouth and tongue, halitosis.The noxious bacteria that oral disease produces enters into after blood, can produce impact in various degree to whole body health, even becomes the Important cause of disease of some general diseases.Modern medicine study shows, oral disease and hormonal system, the cardiovascular system respiratory system etc. of unifying all has close relationship.For example: simulation experiment proves that streptococcus and periodontal disease substance, after wound intravasation, can impel generation effect to be similar to the gluey protein of hematoblastic one, and it can impel blood coagulation.This gluey protein is attached in blood vessel wall, accumulates over a long period and will form coronary atherosclerosis, and artery-clogging when serious, causes ischemia and support deficiency, thereby causes heart attack.The cytokine that oral disease causes has destructiveness, is unfavorable for health, and too much cytokine can be destroyed pancreas islet gland, reduces the secretory volume of the necessary insulin of human body, easily causes the generation of type Ⅱdiabetes mellitus.Other can cause gravid woman's premature labor, aspiration pneumonitis, gastroenteropathy etc. in addition, can say, heart disease, diabetes etc. is all the complication of oral disease.Therefore oral disease not only affects patient's oral health, as treatment not in time, can be to a great extent patient healthy be caused to great threat.
Before the present invention makes, the products such as existing water-soluble chitosan collutory, tea polyphenols collutory use clinically, but because of self fungistatic effect single, higher to concentration requirement, or need could arrive fungistatic effect with high concentration ethanol synergism, so that narrow antimicrobial spectrum, result of use is poor, mouthfeel is not good, and patient is difficult to the reasons such as acceptance, and causes being difficult to apply.
[summary of the invention]
For solving the problems of the technologies described above, the present invention aims to provide a kind of chitosan collutory and preparation method thereof, this collutory has good antimicrobial effect, concentration requirement is low, mouthfeel good, and does not need and the synergistic advantage of high concentration ethanol, is therefore conducive to apply.
For solving the problems of the technologies described above, the present invention has adopted following technical proposals, and this chitosan collutory is made up of the material composition of following weight portion:
20～50 parts of chitosans
0.10～0.50 part of natamycin
0.2～0.80 part of polylysine
5～10 parts of aspartames
5～10 parts of Oleum menthae
5～10 parts of Fructus Citri Limoniae essence
Purified water adds water to 5000～10000 parts.
A preparation method for chitosan collutory as above, its step is as follows:
Get purified water, add according to quantity chitosan, natamycin, polylysine, aspartame, heating makes to dissolve; To be cooled, add essence and Oleum menthae, add purified water to full dose, measuring pH value is 6.5, obtains product.
Beneficial effect: compared with prior art, inventor, in chitosan, has added two kinds of broad-spectrum antibacterial agents of polylysine and natamycin, makes collutory, can give full play to the advantage of three kinds of antibacterial aspects of the each leisure of medicine.
Chitosan (chitosan) is that the chitin (chitin) extensively being existed by nature obtains through deacetylation, chemical name is Chitosan (1-4)-2-amino-B-D glucose, from 1859, first Frenchman Rouget obtains after chitosan, and the premium properties such as the biological functionality of this natural polymer and the compatibility, blood compatibility, safety, microbic resolvability are by all trades and professions extensive concern.Chitosan and derivant thereof have good antibacterial activity, can suppress the growth and breeding of some funguses, antibacterial and virus.Think that at present its possible mechanism has three: one, due to the polycation of chitosan, be easy to the group effect of fungal cell's surface band negative charge, thereby change mobility and the permeability of pathogen cell membrane; The 2nd, disturb copying and transcribing of DNA; The 3rd, the metabolism of blocking-up pathogen.
Epsilon-polylysine (ε-PL, molecular formula C180H362N60) is Japan's synthetic auxotype antibacterial at first, and it is a kind of poly-l-lysine that connects carboxyl and amino group by peptide bond, is a kind of polypeptide with bacteriostasis efficacy.Because it has special molecular structure, thereby there is special physics, chemistry and pharmacological properties.
Epsilon-polylysine has strong bacteriostasis.It can destroy microorganisms membrane structure, cause that material, energy and the information transmission of cell interrupted, finally cause cell death.Gram positive bacteria, gram negative bacteria, yeast, mycete are all had to good fungistatic effect, and very good to difficult escherichia coli, the Salmonella fungistatic effect suppressing of other antibacterial, thermostability bacillus cereus and some viruses are also had to inhibitory action.
Epsilon-polylysine has high safety.It enters nutrition aminoacid---the lysine that can be decomposed into needed by human after human body, and the lysine eight necessary seed amino acids that are human body.Japan lists epsilon-polylysine in the natural additive that allows interpolation in food in 1989, has also listed food additive scope at US and European.
Epsilon-polylysine good stability, has the features such as good water solubility, heat stability and the pH scope of application are wide, under various different conditions, all can use.Experiment shows, 80 DEG C of processing 60 min of its aqueous solution, 100 DEG C of processing 30min, 120 DEG C of processing 20min character are all stablized, constant to colibacillary minimal inhibitory concentration, after heat treatment heat sterilization, microorganism is still had to bacteriostatic activity, and fungistatic effect is relatively stable in pH 5～8 scopes.
Other antibiotic property materials such as epsilon-polylysine and ethanol, glycine, thiamine alkyl sulfate have good cooperative effect, for example polylysine is 50ug/ml for colibacillary minimal inhibitory concentration, ethanol is 5% for colibacillary minimal inhibitory concentration, and both mix use and only need 0.025% ethanol of 5ug/ml polylysine just escherichia coli just to be had to strong inhibitory action.Epsilon-polylysine and other biological antiseptic, as compound uses such as glycine, malic acid, acetic acid, lactic acid natamycins, not only can make up the epsilon-polylysine deficiency poor to mycete fungistatic effect, and the corresponding consumption that reduces polylysine, thereby reduce the use cost of antibacterial.
Natamycin has antibacterial activity to nearly all yeast and mycete, but invalid to antibacterial, protozoacide or sick element.Most of mycetes just can be suppressed in the time of concentration 0.5～6ug/mL, but some mycete needs l0～25ug/mL.Most of yeast just can be suppressed in the concentration of 1.0～5.0ug/mL; Under 22 mg/kg concentration, effect has killing action to Candida albicans, Aspergillus flavus.
At present, there is no the chitosan collutory listing of similar formula and the report using, also there is no the report that uses separately epsilon-polylysine, natamycin to apply as collutory.This product is the excellent product for the treatment of and prevention oral disease, can use at clinical expansion.
Experimental example one:
Research title: the In-vitro Inhibitory Effect of chitosan collutory to several oral cavities common pathogen.
Research purpose: the In-vitro Inhibitory Effect of the chitosan collutory of research variable concentrations to oral cavity common pathogen.
Research method: adopt scraps of paper drug sensitive test, detect the inhibition zone diameter of variable concentrations chitosan oral liquid to staphylococcus aureus, Candida albicans, helicobacter pylori, porphyromonas gingivalis and Streptococcus mutans; Measure the impact of different disposal method on its fungistatic effect.Between group, relatively adopt random blocking design variance analysis, completely randomized design variance analysis and t inspection.
Validity result:
The chitosan collutory of variable concentrations all has inhibitory action to staphylococcus aureus, Candida albicans, helicobacter pylori, porphyromonas gingivalis, Streptococcus mutans, and increases with concentration, and bacteriostasis strengthens; Chitosan bacteriostasis through high-temperature process is stable, with the matched group comparison of bacteriostatic agent hibitane composition, and no significant difference (P>0.05).
Safety results:
Contrast the medicine group laboratory abnormalities incidence rate relevant with safety suitable.
Conclusion: chitosan collutory has inhibitory action to oral cavity common pathogen.
Experimental example two:
Research title: chitosan collutory extracorporeal bacteria inhibitor test research.
Research purpose: compare with effective anti anaerobic bacteria infection medicine hibitane of generally acknowledging at present, chitosan collutory is suppressed to the effect of infectious root canal antibacterial and carry out laboratory observation.
Research method: the important pathogenic bacteria of selecting generally acknowledged dental pulp and periapical infection is tested strain: Porphyromonas endodontalis in vitro, porphyromonas gingivalis, middle general Salmonella and G+ bacterium actinomyces viscosus.Adopt dish agar diffusion method to carry out bacteriostatic experiment.Use SPSS11.5 statistics software, adopt variance analysis and Student-Newman-Keuls method of randomized block design to carry out statistical analysis.
Validity result:
1, the minimal inhibitory concentration value there was no significant difference (P >0.05) of the matched group of chitosan collutory and bacteriostatic agent hibitane composition to each tested bacterium.
2, the fungistatic effect no difference of science of statistics of chitosan collutory and matched group hibitane (P >0.05).
Conclusion: effect and hibitane that chitosan collutory suppresses infectious root canal antibacterial are equal to.
Below in conjunction with embodiment, the invention will be further described.
[detailed description of the invention]
Embodiment 1:
46 parts of chitosans
0.12 part of natamycin
0.4 part of polylysine
8 parts of aspartames
Oleum menthae 8ml part
Fructus Citri Limoniae essence 8ml part
Purified water adds water to 8000 parts
Step is as follows:
The preparation of chitosan collutory: get purified water, add chitosan, polylysine, natamycin, aspartame, heating makes to dissolve.After natural cooling, add essence and Oleum menthae, add purified water to full dose, regulating pH value is 6.5.
Embodiment 2:
46 parts of chitosans
0.12 part of natamycin
0.4 part of polylysine
8 parts of aspartames
8 parts of Oleum menthae
8 parts of Fructus Citri Limoniae essence
Purified water adds water to 8000 parts
Step is as follows:
The preparation of chitosan collutory: get purified water, add chitosan, polylysine, natamycin, aspartame, heating makes to dissolve.After natural cooling, add essence and Oleum menthae, add purified water to full dose, regulating pH value is 6.5.
Clinical trial: result shows that embodiment product can significantly reduce the bacterial population in oral cavity in clinical use procedure, the growth of anti-bacteria, test forward and backward subject oral cavity bacteria in crevicular fluid and cultivate counting statistical analysis P<0.0001, have significant difference; To the overall effective percentage 94.00% of halitosis treatment, before and after treatment, halitosis scoring has significant difference; The total effective rate that treatment is improved to oral ulcer is 95.65%, and experimenter uses the overall satisfaction rate to 96.87% of embodiment product.The results show embodiment product can be used for suppressing the growth of oral cavity bacterium, anti-halitosis in advance, and to the treatment of the diseases such as oral ulcer, clinical efficacy is obvious.Embodiment Product Safety is good, and untoward reaction and serious adverse events do not occur in use procedure.
Claims (2)
1. a chitosan collutory, is characterized in that: the material composition by following weight portion forms:
20～50 parts of chitosans
0.10～0.50 part of natamycin
0.2～0.80 part of polylysine
5～10 parts of aspartames
5～10 parts of Oleum menthae
5～10 parts of Fructus Citri Limoniae essence
Purified water adds water to 5000～10000 parts.
2. a preparation method for chitosan collutory as described in claim 1, is characterized in that: get purified water, add according to quantity chitosan, natamycin, polylysine, aspartame, heating makes to dissolve; To be cooled, add essence and Oleum menthae, add purified water to full dose, measuring pH value is 6.5, obtains product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310392974.4A CN103932914B (en) | 2013-09-03 | 2013-09-03 | Chitosan collutory and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310392974.4A CN103932914B (en) | 2013-09-03 | 2013-09-03 | Chitosan collutory and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103932914A true CN103932914A (en) | 2014-07-23 |
| CN103932914B CN103932914B (en) | 2016-06-08 |
Family
ID=51180976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310392974.4A Active CN103932914B (en) | 2013-09-03 | 2013-09-03 | Chitosan collutory and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103932914B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105963237A (en) * | 2016-07-06 | 2016-09-28 | 广东科玮生物技术股份有限公司 | Novel gargle and preparation method as well as application thereof |
| CN106176546A (en) * | 2016-08-26 | 2016-12-07 | 湖北立天生物工程有限公司 | Based on the cleaning of the chitosan derivatives degree of depth, bacteriostatic tooth protective collutory and preparation method thereof |
| CN106473961A (en) * | 2016-12-02 | 2017-03-08 | 丹东康齿灵保洁用品有限公司 | A kind of gargarism and preparation method |
| CN106906053A (en) * | 2017-01-20 | 2017-06-30 | 北京德得创业科技有限公司 | A kind of liquid detergent containing polylysine and shitosan and preparation method and application |
| CN108078849A (en) * | 2017-12-30 | 2018-05-29 | 广州润虹医药科技股份有限公司 | A kind of gargle containing chitosan and preparation method thereof |
| CN110946778A (en) * | 2019-12-19 | 2020-04-03 | 华熙生物科技股份有限公司 | Toothpaste with anti-inflammation and bacteriostasis functions |
| CN114224909A (en) * | 2021-12-22 | 2022-03-25 | 南京康容健康科技有限公司 | Material for treating and preventing bacterial infection, modification method and application |
| CN115369061A (en) * | 2022-08-24 | 2022-11-22 | 山东博科生物产业有限公司 | Selective helicobacter pylori culture medium and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006135854A2 (en) * | 2005-06-10 | 2006-12-21 | Board Of Regents, The University Of Texas System | Antiseptic compositions |
| CN1922203A (en) * | 2004-01-19 | 2007-02-28 | 卢卡斯·海布雷赫特 | Anticariogenic proteins and peptides and saccharides |
| CN102764219A (en) * | 2012-07-27 | 2012-11-07 | 山东克斯特消毒科技股份有限公司 | Sterilizing mouthwash for oral cavities |
-
2013
- 2013-09-03 CN CN201310392974.4A patent/CN103932914B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1922203A (en) * | 2004-01-19 | 2007-02-28 | 卢卡斯·海布雷赫特 | Anticariogenic proteins and peptides and saccharides |
| WO2006135854A2 (en) * | 2005-06-10 | 2006-12-21 | Board Of Regents, The University Of Texas System | Antiseptic compositions |
| CN102764219A (en) * | 2012-07-27 | 2012-11-07 | 山东克斯特消毒科技股份有限公司 | Sterilizing mouthwash for oral cavities |
Non-Patent Citations (2)
| Title |
|---|
| 叶国钦 等: "多聚赖氨酸复合体治疗口腔幽门螺杆菌感染的疗效观察", 《中国医疗前沿》, vol. 5, no. 1, 31 January 2010 (2010-01-31), pages 3 - 4 * |
| 王昆润 译: "治疗口腔粘膜念珠菌病的药物选择", 《国外医药抗生素分册》, vol. 21, no. 2, 31 March 2000 (2000-03-31), pages 95 - 96 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105963237A (en) * | 2016-07-06 | 2016-09-28 | 广东科玮生物技术股份有限公司 | Novel gargle and preparation method as well as application thereof |
| CN106176546A (en) * | 2016-08-26 | 2016-12-07 | 湖北立天生物工程有限公司 | Based on the cleaning of the chitosan derivatives degree of depth, bacteriostatic tooth protective collutory and preparation method thereof |
| CN106473961A (en) * | 2016-12-02 | 2017-03-08 | 丹东康齿灵保洁用品有限公司 | A kind of gargarism and preparation method |
| CN106906053A (en) * | 2017-01-20 | 2017-06-30 | 北京德得创业科技有限公司 | A kind of liquid detergent containing polylysine and shitosan and preparation method and application |
| CN108078849A (en) * | 2017-12-30 | 2018-05-29 | 广州润虹医药科技股份有限公司 | A kind of gargle containing chitosan and preparation method thereof |
| CN110946778A (en) * | 2019-12-19 | 2020-04-03 | 华熙生物科技股份有限公司 | Toothpaste with anti-inflammation and bacteriostasis functions |
| CN114224909A (en) * | 2021-12-22 | 2022-03-25 | 南京康容健康科技有限公司 | Material for treating and preventing bacterial infection, modification method and application |
| CN115369061A (en) * | 2022-08-24 | 2022-11-22 | 山东博科生物产业有限公司 | Selective helicobacter pylori culture medium and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103932914B (en) | 2016-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103932914A (en) | Chitosan mouthwash and preparation method thereof | |
| Vasudeva et al. | Disinfection of dentinal tubules with 2% Chlorhexidine gel, Calcium hydroxide and herbal intracanal medicaments against Enterococcus faecalis: An in-vitro study | |
| EP3223833B1 (en) | Prevention and treatment of microbial infections | |
| CN103893026B (en) | It is a kind of to be used for oral cleaning and the mouthwash of health care | |
| CN105148253B (en) | Skin and mucosa bactericidal composition | |
| US20020155174A1 (en) | Acidified nitrite as an antimicrobial agent | |
| Vahid-Dastjerdi et al. | Effect of Rhus coriaria L. water extract on five common oral bacteria and bacterial biofilm formation on orthodontic wire | |
| US20080286235A1 (en) | Antimicrobials and related methods | |
| CN109316536A (en) | A kind of skin mucosa disinfecting agent and preparation method thereof | |
| CN105055642A (en) | Compound guanidine disinfectant and preparation method of compound guanidine disinfectant | |
| CN105919829A (en) | Mouthwash and preparation method thereof | |
| CN104207957A (en) | Fibroin care solution with functions of contracting genitals and whitening, and preparation method thereof | |
| CN102204880A (en) | Disinfectant gellant for gynaecological external use and its preparation method | |
| CN102405935B (en) | Protamine compounded preparation, preparation method and application thereof | |
| CN109045157A (en) | A kind of bactericidal composition of the extract containing Pudilan, mouthwash and preparation method thereof | |
| CN109010098A (en) | Antimicrobial mouthwash and preparation method thereof | |
| CN106420938B (en) | A kind of Chinese medicine composition and preparation method thereof for treating oral inflammation and pharyngitis | |
| CN107582737A (en) | A kind of compound chlorohexidene oral-cavity disinfectant and preparation method thereof | |
| CN105726390B (en) | A kind of toothpaste for preventing gingivitis | |
| CN110538089A (en) | Antibacterial halitosis-removing pet toothpaste | |
| CN109846786A (en) | A kind of Chinese medicine mouth wash and the preparation method and application thereof | |
| CN105726386B (en) | A kind of toothpaste for preventing plaque | |
| JPH0881348A (en) | External preparation for skin | |
| CN113876657B (en) | Application of cercis chinensis flower extract in oral care products | |
| CN114191326B (en) | Oral care product containing zinc complex of momordica grosvenori acid B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 324000 No. 889 Century Avenue, Quzhou Economic Development Zone, Zhejiang, China Applicant after: ZHEJIANG KANGDE PHARMACEUTICAL CO., LTD. Address before: 324000 No. 889 Century Avenue, Quzhou Economic Development Zone, Zhejiang, China Applicant before: Zhejiang Kangde Pharmacy Group Co., Ltd. |
|
| COR | Change of bibliographic data | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |